Evaluating biological aging markers in Hodgkin's lymphoma patients
Official title: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06761274 · Data updated 2026-11-12
This study is trying to see if certain biological markers can help us understand how aging affects people with Hodgkin's lymphoma who are in remission or newly diagnosed.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | November 3, 2022 |
| Main results expected | September 30, 2025 |
| Study ends | September 30, 2025 |
| Registry record updated | January 7, 2025 |
| Trial ID | NCT06761274 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with Hodgkin's lymphoma in complete remission for at least two years or newly diagnosed patients requiring first-line therapy.
✕Probably not a fit
Patients with concomitant second neoplasms will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates epigenetic and inflammatory markers associated with accelerated biological aging in patients with Hodgkin's lymphoma. It focuses on individuals who are either in complete remission for at least two years after first-line therapy or newly diagnosed with advanced stages of the disease. The research involves analyzing peripheral blood samples to understand the long-term health implications and risks of secondary malignancies in these patients. The study is exploratory and aims to provide insights into the biological aging processes in this specific patient population.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for long-term survivors of Hodgkin's lymphoma.
How similar studies have gone: While this approach is exploratory, similar studies have shown promise in understanding the long-term effects of cancer treatments on biological aging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma * Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy * Patients of both sexes aged ≥ 18 years at enrollment * Signature of informed consent Exclusion Criteria: * Concomitant second neoplasm
Where it's running
-
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Pier Luigi Zinzani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Pier Luigi Zinzani, MD
- Email: pierluigi.zinzani@unibo.it
- Phone: +390512144042
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of dexrazoxane on heart health in cancer survivors
This study tests if the drug dexrazoxane can help protect the heart health of cancer survivors who had leukemia, lymphoma, or osteosarcoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.